Overview: PML RARA t(15;17) Quantitative PCR TestIntroduction: The PML RARA t(15;17) Quantitative PCR Test detects PML-RARA to diagnose leukemia, causing fatigue or bleeding. Aligned with 2023 ASCO guidelines, it uses PCR for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected acute promyelocytic leukemia (APL).
Other Names: PML-RARA PCR Assay, APL Diagnostic Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: PML-RARA testing began in the 1990s with APL research. PCR methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects PML-RARA to diagnose leukemia, guides treatment, and evaluates patients with fatigue or bleeding.
Test Parameters: 1. PML-RARA t(15;17) Detection
Pretest Condition: No fasting required. Collect whole blood or bone marrow. Report history of fatigue, bleeding, or leukemia symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Bone Marrow (EDTA, 2-5 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, bleeding, or family history of leukemia. Include current medications, especially chemotherapy agents.
Consent: Written consent required, detailing the tests purpose, leukemia implications, and risks of sample collection.
Procedural Considerations: Uses quantitative PCR to detect PML-RARA t(15;17). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for APL diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Positive PML-RARA confirms APL, guiding ATRA or arsenic trioxide therapy. Negative results may require additional genetic testing.
Specialist Consultation: Consult an oncologist or hematologist for result interpretation and treatment planning.
Additional Supporting Tests: Bone marrow cytology, FISH, or flow cytometry to confirm APL diagnosis.
Test Limitations: Not all APL cases are PML-RARA positive; clinical correlation is needed. Sample quality affects sensitivity.
References: ASCO Leukemia Guidelines, 2023; Blood, Sanz MA, 2022.
